Improvement of glycemic control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin, this medication should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually.
To maintain its extended-release properties, this medication must be swallowed whole without splitting, crushing, grinding, or chewing.
Take 1 tablet of this medication 100/1000 mg extended-release tablet once daily.
Patients taking this medication 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily.
1. Patients not currently receiving metformin:
For patients with no prior experience of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medication is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Do not administer to the following patients).
2. Patients receiving metformin:
- The recommended initial total daily dose of this medication for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and their current dose of metformin.
- Patients switching to this medication from concomitant sitagliptin and metformin therapy may start at their current doses of sitagliptin and metformin.
- Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medication 50/1000 mg extended-release tablet once daily.
3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial total daily dose of this medication is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose.
Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions).
Patients with renal impairment
This medication may be used, with the following dosage adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis.
Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be carefully monitored every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately.
Patients with hepatic impairment
This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
Improvement of glycemic control in patients with type 2 diabetes
View approved original textHide original text
This medication is used along with dietary and exercise regimens to assist in blood sugar control for patients with type 2 diabetes. Sitagliptin and metformin work together to effectively improve blood sugar levels, thereby supporting patients in maintaining more stable blood sugar management.
How to take
Adult dose
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin, this medication should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually.
To maintain its extended-release properties, this medication must be swallowed whole without splitting, crushing, grinding, or chewing.
Take 1 tablet of this medication 100/1000 mg extended-release tablet once daily.
Patients taking this medication 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily.
1. Patients not currently receiving metformin:
For patients with no prior experience of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medication is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Do not administer to the following patients).
2. Patients receiving metformin:
- The recommended initial total daily dose of this medication for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and their current dose of metformin.
- Patients switching to this medication from concomitant sitagliptin and metformin therapy may start at their current doses of sitagliptin and metformin.
- Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medication 50/1000 mg extended-release tablet once daily.
3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial total daily dose of this medication is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose.
Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions).
Patients with renal impairment
This medication may be used, with the following dosage adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis.
Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be carefully monitored every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately.
Patients with hepatic impairment
This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
Precautions
This medication contains sitagliptin and metformin and is primarily used for blood sugar control in patients with type 2 diabetes.
When taking this medication, severe allergic reactions, such as anaphylaxis, angioedema, and severe skin disorders may occur, so if such symptoms appear, immediately stop taking the medication and consult a doctor.
Additionally, acute pancreatitis, which is a serious side effect causing inflammation of the pancreas, has been reported. Therefore, if symptoms of pancreatitis such as abdominal pain, nausea, or vomiting occur during the initial dosage or while taking the medication, inform medical personnel immediately.
This medication should not be administered to patients with severely impaired kidney function or those with specific conditions such as heart failure, acute myocardial infarction, or serious infections, and it should also be withheld when undergoing examinations involving iodine contrast agents.
It is advisable for pregnant women, women who may become pregnant, nursing mothers, and children under the age of 18 not to use this medication.
This medication may cause hypoglycemia, so it is important to eat regularly, and if taken with other hypoglycemic agents, one should be cautious of hypoglycemia symptoms.
The metformin component can rarely cause lactic acidosis, a severe metabolic disorder, so particular caution should be taken in patients with poor kidney function, liver dysfunction, dehydration, or excessive alcohol consumption.
Regular monitoring of kidney function and blood tests to check liver and kidney status, as well as monitoring of vitamin B12 levels, is recommended.
Temporarily discontinue this medication in situations such as surgery, severe infection, and serious trauma, and restart only after symptoms have improved and kidney function has returned to normal.
During the use of this medication, avoid excessive alcohol consumption, and inform healthcare personnel if the medication is not being absorbed properly and is being excreted in the stool.
Finally, this medication may interact with other drugs, so if you are taking other medications, it is essential to inform your doctor or pharmacist, especially in elderly patients or those with impaired kidney function.
Side effects
Anaphylaxis
angioedema
Stevens-Johnson syndrome
acute pancreatitis
lactic acidosis
hypoglycemia
diarrhea
upper respiratory tract infection
headache
nausea
Show 20 moreCollapse
vomiting
abdominal pain
nasopharyngitis
constipation
severe joint pain with disability
bullous pemphigoid
myalgia
limb pain
back pain
interstitial lung disease
pruritus
thrombocytopenia
rhabdomyolysis
rash
urticaria
cutaneous vasculitis
elevated liver enzymes
acute renal failure
hypoglycemia
peripheral edema
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly closed container to protect it from air and moisture, and it is safe to keep it at room temperature, between 1 and 30 degrees Celsius.
By storing it this way, you can maintain the efficacy of the medication and prevent degradation.
Appearance and packaging
Appearance
Bright blue, oval-shaped extended-release film-coated tablet with a convex surface on both sides
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.